Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

List of clinical trials for Hepatology (Liver, Pancreatic, Gall Bladder) therapeutic area

Hepatology (Liver, Pancreatic, Gall Bladder)

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

With Fermion, start the journey of your innovative API.

Contact Supplier

Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Filters

FILTER :

filter Interventions

All

Insulin

filter Therapeutic Area

All

Hepatology (Liver, Pancreatic, Gall Bladder)

filter Condition

All

Nonalcoholic steatohepatitis

filter Study Phase

All

Phase II

filter Location

All

Israel

Oramed Pharmaceuticals

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

U.s.a

Digital Content

An Open-Label Pilot Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Potential of Oral Insulin to Reduce Liver Fat Content...

Highest Development Status: Phase II

Therapeutic Area: Hepatology (Liver, Pancreatic,...

Interventions: Insulin

Product Type: Large molecule

Sponsor: Oramed Ltd.

Receptors: Insulin receptor agonist

Trial ID: NCT02653300

Location: Israel

Condition: Nonalcoholic steatohepatitis

Product Status: Approved

Dosage Form: Soft gel capsule

Collaborator: Hadassah Medical Organ...

Recruitment Status: Recruiting

Date Of Registration: 24-12-2015

Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.

01

Oramed Pharmaceuticals

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

Oramed Pharmaceuticals

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Highest Development Status: Phase II

Therapeutic Area: Hepatology (Liver, Pancreatic,...

Interventions: Insulin

Location: Israel

Sponsor: Oramed Ltd.

Trial ID: NCT02653300

An Open-Label Pilot Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Potential of Oral Insulin to Reduce Liver Fat Content and Fibrosis in Patients With Nonalcolholic Steatohepatitis (NASH)

Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.

Product Status: Approved

Dosage Form: Soft gel capsule

Collaborator: Hadassah Medical Organ...

Recruitment Status: Recruiting

Date Of Registration: 24-12-2015

Condition: Nonalcoholic steatohepatitis

Product Type: Large molecule

Receptors: Insulin receptor agonist

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

First

Last